In our study, neither FRMD6 gene hypomethylation nor protein expression was associated with any clinicopathological variable, except for a clear association with a lower level of PD-L1 expression, a biomarker that predicts which patients with different types of cancer are more likely to respond to immunotherapy [49]. Here, FRMD6 is linked to cancer.